LDS/Medical Tests/Micrometastasis Detection

Micrometastasis Detection

Cancers spread by way of individual cells leaving their primary site, such as colon, and moving by way of the blood or lymphatic systems (metastasizing) to other locations such as lung and liver. The types of cancers that do this are cancers of epithelium (carcinomas) and cancers of soft tissue (sarcomas). Cancers of the immune system (lymphomas and leukemias) are systemic from onset by definition and the term metastasis does not apply to them. Virtually all work in the detection of metastatic cancer has been done with carcinomas, primarily breast, lung, and colon. Much work has also been done with malignant melanoma, but this is technically not a carcinoma. Prognosis in carcinomas is related primarily to stage, i.e., the extent of the malignancy, both size, involvement of adjacent organs and presence of metastases. Treatment often varies depending on the stage of the carcinoma; therefore, assessment for the presence of metastases has important therapeutic as well as prognostic implications.

Until recently, the ability to detect the presence of metastases was limited by physical examination, X-ray, and Computed tomography (CT imaging). Recently Magnetic Resonance Imaging (MRI) has proven useful. Sometimes these detection modalities are combined with biopsy and examination by light microscopy. Recently, evaluation of metastatic status of certain carcinomas has utilized removal of the primary tumor in combination with microscopic examination of the first few lymph nodes in the tumor lymphatic drainage for the presence of microscopic metastatic cancer cells, a procedure known as sentinel lymph node biopsy. Sentinel node biopsy also routinely utilizes the methodology of immunohistochemistry to test for the presence of rare tumor cells too small and isolated to be detected reliably by routine light microscopy.

Even more recently, techniques have been developed to detect for the presence of individual tumor cells in the blood stream (circulating tumor cells). Individual or small collections of tumor cells too small to be seen with the unaided eye in these distant sites have been termed micrometastases to emphasize their extremely small size and difficulty of detection. Detection of individual circulating tumor cells requires the use of concentrating techniques such as density centrifugation, filtration, and other methods prior to the application of molecular detection methods such as immunohistochemistry and immunofluorescence followed by microscopic examination by a trained individual.

  • Cancer/disease diagnostics and prognostics purposes
  • Disease and therapy management
  • Disease (cancer) staging and progression evaluation
  • Evaluate, manage, and monitor therapy treatment
Patients with malignant tumor cells present only in the primary tumor site, such as breast, and nowhere else are called free of metastasis. Patients with tumor cells in other organs away from the primary tumor, such as lymph nodes, are said to have metastatic disease.

Localized disease (lower stage disease): Absence of metastasis
Metastatic disease (higher stage disease): Presence of metastasis

 

Immunohistochemistry, Immunofluorescence, Polymerase Chain Reaction, Flow cytometry, Immunomagnetic Cell Separation.

Tissue for sentinel lymph node biopsy is collected by the surgeon and sent fresh without fixative immediately to the laboratory for analysis.

Tissue for routine tissue light microscopic analysis is submitted in formalin fixative to the laboratory.

Peripheral blood for circulating tumor cell detection is collected by veinipuncture into EDTA tubes (whole blood) and shipped to the laboratory performing the test.

Sentinel lymph node biopsy, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Flow cytometry, Polymerase chain reaction, Serum tumor markers, Prostate specific antigen, Carcinoembryonic antigen, CA19-9, CA-125, Fluorescence In Situ Hybridization.
Sentinel lymph node biopsy: Intra-operative, real time. Sentinel lymph node biopsy immunohistochemistry: 2-3 business days. Peripheral blood analysis by Immunonomagnetic Cell Separation: 4 business days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login